Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.26663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Dana Shalmon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Pemphigoid, Bullous, Diabetes Mellitus, Type 2, Dementia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes. A retrospective study was conducted in a tertiary centre among diabetic patients exposed to gliptins between the years 2008–2021. Data including demographics, comorbidities, medications, and laboratory results were collected using the MDClone platform. Seventy-six patients with type 2 diabetes treated with dipeptidyl-peptidase 4 inhibitors who subsequently developed bullous pemphigoid were compared with a cohort of 8,060 diabetic patients exposed to dipeptidyl-peptidase 4 inhibitors who did not develop bullous pemphigoid. Based on a multivariable analysis adjusted for age and other covariates, Alzheimer’s disease and other dementias were significantly more prevalent in patients with bullous pemphigoid (p = 0.0013). Concomitant use of either thiazide or loop diuretics and gliptin therapy was associated with drug-associated bullous pemphigoid (p < 0.0001 for both). While compared with sitagliptin, exposure to linagliptin and vildagliptin were associated with bullous pemphigoid with an odds ratio of 5.68 and 6.61 (p < 0.0001 for both), respectively. These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer’s and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- School of Public Health, University of Haifa, Haifa, Israel.
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. mashapavl@gmail.com.
Zitieren
APA
Shalmon, D., Bar-Ilan, E., Peled, A., Geller, S., Bar, J., Schwartz, N., Sprecher, E., & Pavlovsky, M. (2024). Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.26663
Vancouver
Shalmon D, Bar-Ilan E, Peled A, Geller S, Bar J, Schwartz N, et al. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.26663
BibTeX
@article{Shalmon2024,
author = {Shalmon, Dana and Bar-Ilan, Efrat and Peled, Alon and Geller, Shamir and Bar, Jonathan and Schwartz, Naama and Sprecher, Eli and Pavlovsky, Mor},
title = {Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.26663}
}
EUVIMED